Filters: Akiyama-2019b is   [Clear All Filters]
Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of HCV antibody-positive deceased donor kidneys in the era of direct-acting antiviral therapy. Transplantation. 2018;102:2088-2095.
Boyle A, Marra F, Peters E, et al. Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. J Viral Hepat. 2020;27(4):371-375.
Brau N, Salvatore M, RÍos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44(1):47-55.
Braun DL, Hampel B, Nguyen H. A treatment as prevention trial to eliminate HCV in HIV+ MSM: the Swiss HCVree trial [abstract 81LB]. 25th Conference on Retroviruses and Opportunistic Infections. 2018.
Braun DL, Hampel B, Kouyos R, et al. High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus-coinfected men who have sex with men. Clin Infect Dis. 2019;68(4):569-576. doi:10.1093/cid/ciy547.
Bravo MJ, Vallejo F, Barrio G, et al. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy. 2012;23(5):415-419.
Brooks KM, Castillo-Mancilla JR, Morrow M, et al. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020;75(11):3303-3310.
Brooks KM, Castillo-Mancilla J, Morrow M, et al. Plasma and intracellular pk and renal safety of TAF 25mg with boosted PIs and LDV/SOF [abstract 449]. Presented at Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. 2020.
Brown RS, Buti M, Rodrigues L, et al. Efficacy and safety of 8-week glecaprevir/pibrentasvir in treatment-naive patients with chronic hepatitis c virus genotype 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis: EXPEDITION-8 complete results [abstract LP9]. Presented at Liver Meeting, 2019; November 8-12. 2019.
Brown, Jr RS, Collins MA, Strasser SI, et al. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther. 2022;11(2):913-924. doi:10.1007/s40121-022-00599-8 .
Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441-449.
Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24-33.
Brown RS, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7]. The Liver Meeting. 2018.
Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?. Sex Transm Infect. 2004;80(4):326-327.
Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2(8):585-594.
Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57(Suppl 2):S56-S61.
Bruix J, Sherman M, AASLD . Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022.
Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis. 2014;58(6):755-761.
National Academies of Sciences, committee on a national strategy for the elimination of hepatitis B and C, board on population health and public health practice: a national strategy for the elimination of hepatitis B and C: phase two report. Washington, DC: National Academies Press; 2017.
Burton MJ, Voluse AC, Anthony V. Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program. J Subst Abuse Treat. 2019;(98):9-14.